Sep 28, 2022
Sharon L. Rogers Ph.D. is the CEO of AmyriAD Therapeutics and has a deep understanding of the development of drugs to address the impact of Alzheimer's disease. Currently, the most common treatment is Aricept which Sharon developed and brought to market in 1996. Based on recent research, it does not appear that disease modification leads to clinical benefit or reduction in the progression of the disease.
Sharon explains, "We're not doing anything that's going to modify the underlying progression of the disease, at least that we know of. This is a relentless disease, and sooner or later, it will run its course, and the outcome is ultimately fatal. But, we can buy time for people. Whenever you can improve function, you can reduce reliance on skilled nursing care. You can reduce reliance on the caregiver and the burden that it brings to the loved ones of the patients. You can prolong the time to nursing home placement, which is just really horrible for everyone involved, the families and the patients."
"It is a simple tablet that will be administered once a day by mouth with just a little bit of water going with it. And as a matter of fact, this drug is designed to be administered as an adjunct to Aricept. Aricept is the standard of care. And so we want to maintain the Aricept treatment, but when you give AD101 on top of it as an oral drug, it increases the effects that were there before. So you'd have an additive improvement in cognition and global function."
@AmyriAD_Tx #Alzheimersdisease #Alzheimers #AD #BrainHealth #MentalHealth #AlzheimersAwareness #MemoriesAreWorthFightingFor